Skip to main content
Erschienen in: European Radiology 2/2021

18.08.2020 | Hepatobiliary-Pancreas

Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid–enhanced MRI

verfasst von: Sunyoung Lee, Seung-seob Kim, Heejin Bae, Jaeseung Shin, Ja Kyung Yoon, Myeong-Jin Kim

Erschienen in: European Radiology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The current LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) determined by only major features provide high specificity, but unsatisfactorily low sensitivity for the noninvasive diagnosis of hepatocellular carcinoma (HCC). This study aimed to identify significant ancillary features (AFs) in LI-RADS version 2018 and develop the upgraded LR-5 criteria to improve diagnostic performance on gadoxetic acid–enhanced magnetic resonance imaging (MRI).

Methods

This retrospective study included 280 patients (366 observations including 281 HCCs) at high-risk for HCC who underwent gadoxetic acid–enhanced MRI between 2015 and 2017. Two readers evaluated major features and AFs for each observation and assigned a LI-RADS category. Independently significant AFs were identified through logistic regression analysis. Upgraded LR-5 criteria were developed by combining independently significant AFs with LR-4 assigned by major features alone. Sensitivities and specificities of the diagnostic criteria were compared using McNemar’s test.

Results

Two of the AFs favoring malignancy in general (mild-moderate T2 hyperintensity and hepatobiliary phase hypointensity) and two of the AFs favoring HCC in particular (nonenhancing “capsule” and mosaic architecture) were independently significant features for diagnosing HCC. By using the upgraded LR-5 criteria (LR-4 by major features alone + each aforementioned AF), sensitivities were significantly increased (69.4–76.9%) compared with the standard LR-5 (66.2%; all, p ≤ 0.004), whereas specificities (95.3–96.5%) were not significantly different (96.5%; all, p > 0.999).

Conclusions

Independently significant AFs may be used to upgrade from LR-4 to LR-5 to improve sensitivity without impairing specificity on gadoxetic acid–enhanced MRI.

Key Points

• Independently significant AFs for HCC on gadoxetic acid–enhanced MRI were mild-moderate T2 hyperintensity, hepatobiliary phase hypointensity, nonenhancing “capsule,” and mosaic architecture.
• When LR-4 criteria by major features alone in combination with significant AFs were upgraded to LR-5, sensitivities were higher than the standard LR-5, without impairing specificity.
• Independently significant ancillary features in Liver Imaging Reporting and Data System version 2018 may be used to upgrade from LR-4 to LR-5 to improve sensitivity without impairing specificity on gadoxetic acid–enhanced MRI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263CrossRef Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263CrossRef
3.
Zurück zum Zitat Lee S, Kim SS, Roh YH, Choi JY, Park MS, Kim MJ (2020) Diagnostic performance of CT/MRI liver imaging reporting and data system v2017 for hepatocellular carcinoma: a systematic review and meta-analysis. Liver Int. https://doi.org/10.1111/liv.14424 Lee S, Kim SS, Roh YH, Choi JY, Park MS, Kim MJ (2020) Diagnostic performance of CT/MRI liver imaging reporting and data system v2017 for hepatocellular carcinoma: a systematic review and meta-analysis. Liver Int. https://​doi.​org/​10.​1111/​liv.​14424
4.
Zurück zum Zitat Lee S, Kim MJ, Kim SS et al (2020) Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 14:70–79CrossRef Lee S, Kim MJ, Kim SS et al (2020) Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 14:70–79CrossRef
5.
Zurück zum Zitat Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H (2019) LI-RADS v2014 categorization of hepatocellular carcinoma: intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol 29:401–410CrossRef Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H (2019) LI-RADS v2014 categorization of hepatocellular carcinoma: intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol 29:401–410CrossRef
6.
Zurück zum Zitat Min JH, Kim JM, Kim YK et al (2018) Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system. Hepatology 68:2254–2266CrossRef Min JH, Kim JM, Kim YK et al (2018) Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system. Hepatology 68:2254–2266CrossRef
7.
Zurück zum Zitat Hope TA, Fowler KJ, Sirlin CB et al (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40:613–625CrossRef Hope TA, Fowler KJ, Sirlin CB et al (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40:613–625CrossRef
8.
Zurück zum Zitat Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef
9.
Zurück zum Zitat Cerny M, Chernyak V, Olivie D et al (2018) LI-RADS version 2018 ancillary features at MRI. Radiographics 38:1973–2001CrossRef Cerny M, Chernyak V, Olivie D et al (2018) LI-RADS version 2018 ancillary features at MRI. Radiographics 38:1973–2001CrossRef
10.
Zurück zum Zitat Korean Society of Abdominal Radiology (2017) Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 18:427–443CrossRef Korean Society of Abdominal Radiology (2017) Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 18:427–443CrossRef
11.
Zurück zum Zitat Rimola J, Forner A, Tremosini S et al (2012) Non-invasive diagnosis of hepatocellular carcinoma </= 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 56:1317–1323CrossRef Rimola J, Forner A, Tremosini S et al (2012) Non-invasive diagnosis of hepatocellular carcinoma </= 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 56:1317–1323CrossRef
12.
Zurück zum Zitat Choi SH, Byun JH, Lim YS et al (2016) Diagnostic criteria for hepatocellular carcinoma 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 64:1099–1107CrossRef Choi SH, Byun JH, Lim YS et al (2016) Diagnostic criteria for hepatocellular carcinoma 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 64:1099–1107CrossRef
13.
Zurück zum Zitat Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674–1682CrossRef Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674–1682CrossRef
14.
Zurück zum Zitat Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRef Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRef
15.
Zurück zum Zitat Chernyak V, Tang A, Flusberg M et al (2018) LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY) 43:82–100CrossRef Chernyak V, Tang A, Flusberg M et al (2018) LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY) 43:82–100CrossRef
16.
Zurück zum Zitat Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRef Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRef
17.
Zurück zum Zitat Chen N, Motosugi U, Morisaka H et al (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRef Chen N, Motosugi U, Morisaka H et al (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRef
18.
Zurück zum Zitat Min JH, Kim YK, Sinn DH et al (2018) Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdom Radiol (NY) 43:2309–2320CrossRef Min JH, Kim YK, Sinn DH et al (2018) Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdom Radiol (NY) 43:2309–2320CrossRef
19.
Zurück zum Zitat Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66CrossRef Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66CrossRef
20.
Zurück zum Zitat An C, Rhee H, Han K et al (2017) Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol 27:2610–2618CrossRef An C, Rhee H, Han K et al (2017) Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol 27:2610–2618CrossRef
21.
Zurück zum Zitat Cannella R, Furlan A (2018) Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY) 43:1847–1848CrossRef Cannella R, Furlan A (2018) Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY) 43:1847–1848CrossRef
Metadaten
Titel
Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid–enhanced MRI
verfasst von
Sunyoung Lee
Seung-seob Kim
Heejin Bae
Jaeseung Shin
Ja Kyung Yoon
Myeong-Jin Kim
Publikationsdatum
18.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07146-4

Weitere Artikel der Ausgabe 2/2021

European Radiology 2/2021 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.